Figure 2:

Median (IQR) UPCR recorded at baseline and 6 months post-SGLT2i treatment onset in patients (A) with a baseline UPCR <300 mg/g (n = 173) (P = .229) and (B) those with a baseline UPCR ≥300 mg/g (n = 73) (P < .001).